NCT01469871 is a Phase 4 clinical trial of Dressing of wound in Tape Blisters, sponsored by Hopital de l'Enfant-Jesus.

Who is sponsoring NCT01469871?

NCT01469871 is sponsored by Hopital de l'Enfant-Jesus.

What drugs are being tested in NCT01469871?

Interventions in NCT01469871: Dressing of wound, Dressing of wound, Dressing of wound.

What condition does NCT01469871 study?

NCT01469871 studies Tape Blisters, Hip Surgery.

Is NCT01469871 still recruiting?

NCT01469871 is currently completed. Last updated 9 November 2011.

Last reviewed 2011-11-09 · How we verify

NCT01469871

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reduction of Tape Blisters After Hip Surgery. A Prospective Evaluation of Three Types of Dressings.

Completed Phase 4 Last updated 9 November 2011

What this trial tests

Phase 4 trial testing Dressing of wound in Tape Blisters in 150 participants. Completed in 1 January 2010.

Timeline

1 February 2009

Primary endpoint
1 January 2010

1 January 2010

Quick facts

Lead sponsor	Hopital de l'Enfant-Jesus
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	150
Start date	1 February 2009
Primary completion	1 January 2010
Estimated completion	1 January 2010
Sites	1 location across Canada

Drugs / interventions tested

Dressing of wound
Dressing of wound
Dressing of wound

Conditions studied

Tape Blisters — all drugs for Tape Blisters →
Hip Surgery — all drugs for Hip Surgery →

Sponsor

Hopital de l'Enfant-Jesus — full company profile →

Who can join

45 and older, any sex, with Tape Blisters or Hip Surgery. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The prevalence of tape blisters after hip fracture surgery
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 8 days

Sponsor's own description

The purpose of this study is to determine if one of the new types of dressings (MEPORE PRO and/or MEPILEX BORDER ) will reduce the blister rate compared to the currently used HYPAFIX.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01469871 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hopital de l'Enfant-Jesus
Last refreshed: 9 November 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01469871.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing